Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
FDA Approves the First Adjuvant Based H5N1 Bird Flu Vaccine
#1
Pandemrix, the first adjuvant based vaccine is approved by FDA to be used against the H5N1 Bird flu viral infection. The vaccine developed by GlaxoSmithKline’s subunit ID Biomedical is decided to be kept in the control of the United States department of Health and Human Services by including it in the list of National stock pile. Therefore Pandemrix vaccine cannot be commercialized.

H5N1 viral strain, the reason behind the bird flu is a subclass of Influenza A virus. It is a RNA virus and the H5N1 coding represents the type of the viral strain where H stands for the Hemagglutinin portion of the virus which influences the bonding between the virus and the target cell and N stands for the Neuraminidase enzyme which aids the release of the replicated viruses from the infected cell. H5N1 categorized as the High Pathogenic Avian Influenza Virus is highly potential to develop a pandemic among human population when transmitted from human to human. The mortality rates of H5N1 infection is identified to be relatively higher than the H1N1 (swine flu) infection.

Pandemrix gains the status of the first adjuvant vaccine following its approval by FDA against H5N1 bird flu. Adjuvants are the components that prove to enhance the response of the immune system towards the antigenic particles and also considered to be effective on mutant strains of the virus. The efficiency of the Pandemrix vaccine against the bird flu is found to be high along with the adjuvant combination. Earlier the adjuvant based vaccine against H1N1 (swine flu) was rejected by FDA as the Vaccine without the adjuvant was found to be more efficient. There are also reported cases of Narcolepsy recorded in patients who received adjuvant based vaccination.

However the lethality of the H5N1 bird flu, its threat to the global population as a pandemic and the recommendation of the Pandemrix vaccine by the advisory panel to the FDA are the key factors supporting the approval of the vaccine by FDA. Also the adjuvant based vaccine Pandemrix renamed as Pumarix gained the approval by the European regulators. In case of an outbreak of H5N1 the vaccine will be distributed by the Health department of the state to protect the people.

Reference
http://www.reuters.com/article/2013/11/2...XD20131122
http://www.ctvnews.ca/health/fda-approve...z2lTgtr6ZA
http://www.nbcnews.com/health/fda-approv...2D11641784
http://en.wikipedia.org/wiki/Influenza_A...btype_H5N1
http://en.wikipedia.org/wiki/Pandemrix
Like Post Reply
  

Possibly Related Threads…
Thread
Author
  /  
Last Post



Users browsing this thread:
1 Guest(s)

FDA Approves the First Adjuvant Based H5N1 Bird Flu Vaccine00